Business Context and Reporting Period
This Form 6-K filing by NervGen Pharma Corp. covers the period of May 2026. The report discloses positive clinical data from the Phase 1b/2a CONNECT SCI study evaluating the investigational drug NVG-291 for the treatment of chronic tetraplegia (spinal cord injury).
Key Financial Metrics
The filing text does not provide specific financial values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on clinical trial results and does not contain a financial statement or management discussion of financial condition.
Material Changes and Clinical Findings
The primary material change is the announcement of statistically significant biomechanical gait analysis results demonstrating genuine neural recovery with NVG-291 in patients with chronic tetraplegia (mean 3.5 years post-injury). Key findings include:
- Global Treatment Effect: NVG-291 showed a statistically significant effect versus placebo (GTE = +0.45; p=0.0197), indicating a 72.7% probability of treatment benefit.
- Responder Rate: 100% (10/10) of NVG-291 subjects were classified as responders compared to 10% (1/10) of placebo subjects (p=0.0001).
- Speed-Effort Dissociation: Unlike the placebo group, NVG-291 subjects showed speed gains not correlated with increased mechanical effort, suggesting restored neural control rather than compensation.
- Specific Metrics: Significant improvements were observed in coordination (p=0.007), mechanical effort (p=0.038), and postural stability (p=0.044).
Outlook, Risks, and Management Commentary
Management commentary highlights that the analyses were independently conducted by Newton Tech and verified by the Department of Computational Biomedicine at a leading academic medical center. The data supports the hypothesis that NVG-291 drives genuine neural recovery. The filing does not explicitly state future financial guidance, specific risks, or contingencies beyond the inherent nature of clinical development.
Investor Verification Checklist
- Verify the full statistical methodology and raw data from the independent verification by the academic medical center.
- Confirm the timeline and regulatory requirements for advancing NVG-291 from Phase 1b/2a to Phase 3 trials.
- Review the company's cash runway and capital requirements, as this filing does not disclose current liquidity or burn rate.
- Assess the commercial potential of NVG-291 for chronic tetraplegia based on the 100% responder rate in this small cohort.